421/1816US=16 / Estatística
Kumar D, Verma M. Methods in cancer epigenetics and epidemiology. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 273-88. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

CANCER. EPIDEMIOLOGIA; EPIGENETICA; ACETILACAO; BIOMARCADOR; CROMATINA; EPIGENETICA; HISTONA; HISTONA DESACETILASE (HDAC); HISTONA ACETILTRANSFERASE (HAT); METILACAO; METILTRANSFERASE; AVALIACAO DE RISCO; TRIAGEM


422/1816US=16 / Estatística
Singh KK, Kulawiec M. Mitochondrial DNA polymorphism and risk of cancer. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 291-303. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

POLIMORFISMO DE DNA MITOCONDRIAL; RISCO DE CANCER; APOPTOSE; MITOCONDRIA; FOSFORILACAO OXIDATIVA; POLIMORFISMO; ESPECIES REATIVAS DE OXIGENIO


423/1816US=16 / Estatística
Jiang J, Zhang X, Yang H, Wang W. Polymorphisms of DNA repair genes: ADPRT, XRCC1, and XPD and cancer risk in genetic epidemiology. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 305-33. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

POLIMORFISMOS; GENES DE REPARO DO DNA; ADPRT; XRCC1; XPD; RISCO DE CANCER; EPIDEMIOLOGIA GENETICA


424/1816US=16 / Estatística
Xu XC. Risk factors and gene expression in esophageal cancer. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 335-60. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

CANCER DE ESOFAGO; FATORES DE RISCO; EXPRESSAO GENICA; TABAGISMO; ALCOOLISMO; REFLUXO GASTROESOFAGICO; ALTERACOES GENETICAS; CANCER. PREVENCAO; ESOFAGO DE BARRET; ADENOCARCINOMA ESOFAGICO; MUTACAO DO GENE P53; ALTERACAO DO GENE P16; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMAL (EGFR); CADERINA-E; COX-2; QUIMIOPREVENCAO; ACIDOS RETINOICOS; ANTI-INFLAMATORIOS NAO ESTEROIDES; EGCG; CURCUMINA


425/1816US=16 / Estatística
Park JY, Huang Y, Sellers TA. Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 361-85. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

REPARO DE DNA; POLIMORFISMO; EXPOSICAO AMBIENTAL; CANCER DE PROSTATA; SUSCETIBILIDADE AO CANCER


426/1816US=16 / Estatística
Kalt I, Masa SR, Sarid R. Linking the Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to human malignancies. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 387-407. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

HERPESVIRUS ASSOCIADO AO SARCOMA DE KAPOSI (KSHV); HERPESVIRUS HUMANO TIPO 8 (HHV-8); SARCOMA DE KAPOSI; LINFOMA PRIMARIO; DOENCA DE CASTLEMAN


427/1816US=16 / Estatística
Serraino D, Piselli P. Cancer cohort consortium approach: cancer epidemiology in immunosuppressed groups. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 409-19. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

CANCER. FATORES DE RISCO; HIV; IMUNOSSUPRESSAO; RECEPTORES DE TRANSPLANTES; SUL DA EUROPA


428/1816US=16 / Estatística
Lawson JS. Do viruses cause breast cancer?. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 421-38. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

CANCER DE MAMA; VIRUS; VIRUS DE TUMOR MAMARIO DOS RATOS (MMTV); VIRUS DO PAPILOMA HUMANO; HPV; DIETA; ALIMENTO; HORMONIO


429/1816US=16 / Estatística
Chauhan SC, Jaggi M, Bell MC, Verma M, Kumar D. Epidemiology of human papilloma virus (HPV) in cervical mucosa. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 439-56. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

PAPILOMAVIRUS HUMANO; HPV; EPIGENETICA; EPIDEMIOLOGIA; CANCER CERVICAL


430/1816US=16 / Estatística
Dumitrescu RG. Epigenetic targets in cancer epidemiology. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 457-67. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

CANCER. EPIDEMIOLOGIA; EPIGENETICA; HIPERMETILACAO; HIPOMETILACAO; DNA; CROMATINA; DESENVOLVIMENTO DO CANCER; SUSCETIBILIDADE AO CANCER; CANCER DE BEXIGA; CANCER NO CEREBRO; CANCER DE MAMA; CANCER CERVICAL; CANCER COLORRETAL; CANCER DE PULMAO; CANCER DE PROSTATA; CANCER DE OVARIO


431/1816US=16 / Estatística
Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 469-86. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

CANCER DE PULMAO DE CELULAS NAO-PEQUENAS; CANCER DE PULMAO DE PEQUENAS CELULAS; SOBREVIVENCIA; QUALIDADE DE VIDA; FARMACOGENOMICA; PERFIL DE EXPRESSAO GENICA; QUIMIOTERAPIA; RADIOTERAPIA; TOXICIDADE


432/1816US=16 / Estatística
Simon MS, Petrucelli N. Hereditary breast and ovarian cancer syndrome: the impact of race on uptak of genetic counseling and testing. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 487-500. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

CANCER DE MAMA; BRCA1; BRCA2; CUIDADOS PRIMARIOS; CANCER DE OVARIO


433/1816US=19 / Biol/Mol
Hager S, Maitland NJ, Collins A. Prostate cancer stem cells. In: Bapat S. Cancer stem cells: identification and targets. New Jersey: John Wiley & Sons, 2009. p. 111-34. ISBN 978-0-470-12201-3.

CELULAS-TRONCO; CANCER DE PROSTATA; PROSTATA HUMANA; CELULAS EPITELIAIS DA PROSTATA


434/1816US=9 / Quimioterapia
Nersesyan A, Misík M, Knasmüller S. Methods used for the detection of antimutagens: an overview. In: Knasmüller S, DeMarini DM, Johnson I, Gerhäuser C. Chemoprevention of cancer and DNA damage by dietary factors. Weinheim: Wiley-VCH, 2009. p. 211-27. ISBN 978-3-527-32058-5.

DETECCAO DE ANTIMUTAGENOS; MECANISMOS DE PROTECAO DO DNA; ANTIGENOTOXICIDADE; SISTEMA IN VITRO; BIOMONITORIZACAO HUMANA


435/1816US=22 / Urologia
Bukowski RM, Figlin RA, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma: overview. In: ___. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 1-12. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; VHL GENE; PROTEINA VHL; VEGF; PDGF; TERAPIAS RCC


436/1816US=22 / Urologia
Dhanani N, Vocke C, Bratslavsky G, Linehan WM. Molecular genetics in inherited renal cell carcinoma: identification of targets in the hereditary syndromes. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 13-33. ISBN 978-1-58829-737-2.

NEOPLASIAS DE RIM; HIPPLE CON-LINDAU; BHD; BIRT-HOGG-DUBE; FUMARATO HIDRATASE


437/1816US=22 / Urologia
Zhou M. Molecular targets in renal tumors: pathologic assessment. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 35-48. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; NEOPLASIA RENAL PATOLOGIA; CITOGENETICA; PROGNOSTICO


438/1816US=22 / Urologia
Hutson TE, Thakkar S, Cohen P, Borden EC. Interferons and interleukin-2: molecular basis of activity and therapeutic results. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 49-78. ISBN 978-1-58829-737-2.

INTERFERON; INTERLEUCINA; IFN-X2, IL-2; INIBICAO DA ANGIOGENESE; EFEITOS CLINICOS DA IL-2 E IFN


439/1816US=22 / Urologia
Junior Kaelin WG, Geoge DJ. The molecular biology of kidney cancer and its clinical translation into treatment strategies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 79-97. ISBN 978-1-58829-737-2.

VON HIPPEL-LINDAU; HIPOXIA; ANGIOGENESE; HIF; VEGF; KDR; MTOR


440/1816US=22 / Urologia
Rathmell WK, Rini BI. VEGF: biologic aspects and clinical approaches. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 99-118. ISBN 978-1-58829-737-2.

RCC; VEGF; VHL; BEVACIZUMAB; BEVACIZUMABE


Primeira | Anterior | Próxima | Última